DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/f06c1b/pharmaceutical_pri) has announced the addition of Decision Resources, Inc.'s new report "Pharmaceutical Pricing, Reimbursement, and Market Access in Poland, Romania and Ukraine" to their offering.
Poland, Romania, and Ukraine have by far the largest populations in Central and Eastern Europe, and their pharmaceutical markets are experiencing strong growth. To succeed in these markets, however, multinational companies must overcome some daunting obstacles, including underinvestment in healthcare, deficient healthcare infrastructures, limited patient access to health insurance and drug benefits, weak intellectual property protection, and competition from local manufacturers of inexpensive generic drugs.
Questions answered in this report:
In 2009, pharmaceutical sales in Poland totalled $6.6 billion, a 10.1% increase over the preceding year. What is the procedure for setting the prices of new drugs in Poland? What is the scope of the national positive list, and what must manufacturers do to have their products added to this list? What reforms to the pricing system has the Polish government recently proposed? What are the key elements of the government's cost-containment strategy?
Retail drug prices in Romania are among the lowest in the EU; how do the pricing procedures for imported and domestic drugs differ? What are the international implications of Romania's low drug prices? How does the Casei Nationale de Asigurari de Sanatate make drug reimbursement decisions? What changes has the government recently made to the Romanian reference pricing system?
Compared with most other European countries, Ukraine exercises relatively limited control over prescription drug prices. To what extent does the Ukrainian government regulate drug prices, and what reforms has it proposed in recent months? How extensive is reimbursement of prescription medicines in Ukraine? How has the government tried to contain pharmaceutical spending?
Companies Mentioned:
- Agentia Nationala a Medicamentului (ANM; National Medicines Agency)
- Asociatia Romana a Producatorilor Internationali de Medicamente (ARPIM; Romanian Association of International Pharmaceutical Manufacturers)
- Camera Federativa a Medicilor din Romania (CFMR; Federal Chamber of Physicians in Romania)
- Colegiul Farmacistilor din Romania (CFR; College of Romanian Pharmacists)
- European Medicines Agency
- FDA
- Oficiul de Stat pentru Inventii si Marci (OSIM; State Office for Inventions and Trademarks)
- Organization for Economic Cooperation and Development (OECD)
- Pharmaceutical Research and Manufacturers of America (PhRMA)
- U.S. Trade Representative (USTR)
- United Nations Population Division
- World Bank
- World Health Organization
- World Trade Organization
For more information visit http://www.researchandmarkets.com/research/f06c1b/pharmaceutical_pri.